MX2020006351A - Metodo para proporcionar terapia de celiprolol a un paciente. - Google Patents

Metodo para proporcionar terapia de celiprolol a un paciente.

Info

Publication number
MX2020006351A
MX2020006351A MX2020006351A MX2020006351A MX2020006351A MX 2020006351 A MX2020006351 A MX 2020006351A MX 2020006351 A MX2020006351 A MX 2020006351A MX 2020006351 A MX2020006351 A MX 2020006351A MX 2020006351 A MX2020006351 A MX 2020006351A
Authority
MX
Mexico
Prior art keywords
celiprolol
therapy
patient
providing
present disclosure
Prior art date
Application number
MX2020006351A
Other languages
English (en)
Inventor
Michael Frank
Original Assignee
Assist Publique Hopitaux De Paris Ap Hp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publique Hopitaux De Paris Ap Hp filed Critical Assist Publique Hopitaux De Paris Ap Hp
Publication of MX2020006351A publication Critical patent/MX2020006351A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se refiere al campo del tratamiento de una enfermedad huérfana, en particular el tratamiento del síndrome de Ehlers-Danlos vascular (vEDS). Más específicamente, la presente divulgación se relaciona con nuevos regímenes de dosificación de titulación ascendente (por ejemplo, regímenes de dosificación en aumento) eficaces para tratar pacientes con vEDS con celiprolol.
MX2020006351A 2017-12-21 2018-12-19 Metodo para proporcionar terapia de celiprolol a un paciente. MX2020006351A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306890.9A EP3501515A1 (en) 2017-12-21 2017-12-21 Method of providing celiprolol therapy to a patient
US16/184,922 US20190192457A1 (en) 2017-12-21 2018-11-08 Method of providing celiprolol therapy to a patient
PCT/EP2018/085902 WO2019121956A1 (en) 2017-12-21 2018-12-19 Method of providing celiprolol therapy to a patient

Publications (1)

Publication Number Publication Date
MX2020006351A true MX2020006351A (es) 2020-11-24

Family

ID=60954840

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020006351A MX2020006351A (es) 2017-12-21 2018-12-19 Metodo para proporcionar terapia de celiprolol a un paciente.
MX2023006765A MX2023006765A (es) 2017-12-21 2020-07-13 Metodo para proporcionar terapia de celiprolol a un paciente.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006765A MX2023006765A (es) 2017-12-21 2020-07-13 Metodo para proporcionar terapia de celiprolol a un paciente.

Country Status (7)

Country Link
US (4) US20190192457A1 (es)
EP (1) EP3501515A1 (es)
AR (1) AR114012A1 (es)
BR (1) BR112020012095A2 (es)
CA (1) CA3083432A1 (es)
MX (2) MX2020006351A (es)
WO (1) WO2019121956A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501513A1 (en) 2017-12-21 2019-06-26 Assistance Publique-Hôpitaux de Paris (AP-HP) Use of celiprolol for treating kyphoscoliotic ehlers-danlos syndrome
EP3501514A1 (en) 2017-12-21 2019-06-26 Assistance Publique-Hôpitaux de Paris (AP-HP) Use of celiprolol for treating vascular ehlers-danlos syndrome in women during pregnancy and peripartum period

Also Published As

Publication number Publication date
EP3501515A1 (en) 2019-06-26
US20190192457A1 (en) 2019-06-27
US20230142044A1 (en) 2023-05-11
CA3083432A1 (en) 2019-06-27
AR114012A1 (es) 2020-07-08
US20210000770A1 (en) 2021-01-07
MX2023006765A (es) 2023-06-19
US20220062208A1 (en) 2022-03-03
WO2019121956A1 (en) 2019-06-27
US11523997B2 (en) 2022-12-13
BR112020012095A2 (pt) 2020-11-17

Similar Documents

Publication Publication Date Title
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MY189601A (en) Treatment of beta-thalassemia using actrii ligand traps
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
MX2020001727A (es) Terapia de combinacion.
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
MX2023006765A (es) Metodo para proporcionar terapia de celiprolol a un paciente.
MX369090B (es) Sultiame para el tratamiento de apnea del sueño.
RU2014120624A (ru) Способ лечения инсульта
RU2013122842A (ru) Способ лечения синдрома диабетической стопы
UA116484U (uk) Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом
MX2022001200A (es) Metodo para el tratamiento de accidente cerebrovascular usando un derivado triciclico.
RU2012110137A (ru) Способ лечения инсулинорезистентности
UA98863U (en) Method for treating endometrial hyperplasia of patients of reproductive age
MDS20160124U2 (ro) Metodă de profilaxie a limforeii prolongate în tratamentul radical al cancerului glandei mamare la pacientele cu diabet zaharat tip 2
RU2011145997A (ru) Способ лечения пациентов с синдромом &#34;жжения языка&#34;